912796-94-2Relevant academic research and scientific papers
ACTIVATORS OF HUMAN PYRUVATE KINASE
-
Page/Page column 28, (2011/11/13)
Disclosed are pyruvate kinase M2 activators which are compounds of Formula (I), including those of Formula (II), wherein A1, A2, L, R, R1 to R3, X1 to X3, k, n, and m are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer. A1 -NR-L-A2 (I)
2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase
Walsh, Martin J.,Brimacombe, Kyle R.,Veith, Henrike,Bougie, James M.,Daniel, Thomas,Leister, William,Cantley, Lewis C.,Israelsen, William J.,Vander Heiden, Matthew G.,Shen, Min,Auld, Douglas S.,Thomas, Craig J.,Boxer, Matthew B.
supporting information; experimental part, p. 6322 - 6327 (2011/11/29)
Compared to normal differentiated cells, cancer cells have altered metabolic regulation to support biosynthesis and the expression of the M2 isozyme of pyruvate kinase (PKM2) plays an important role in this anabolic metabolism. While the M1 isoform is a highly active enzyme, the alternatively spliced M2 variant is considerably less active and expressed in tumors. While the exact mechanism by which decreased pyruvate kinase activity contributes to anabolic metabolism remains unclear, it is hypothesized that activation of PKM2 to levels seen with PKM1 may promote a metabolic program that is not conducive to cell proliferation. Here we report the third chemotype in a series of PKM2 activators based on the 2-oxo-Naryl-1,2,3,4-tetrahydroquinoline-6-sulfonamide scaffold. The synthesis, structure activity relationships, selectivity and notable physiochemical properties are described.
